| Ημερομηνία | barcode | code | περιεχομενο | τιμή παραγωγός | χονδρική | λιανική |
|---|---|---|---|---|---|---|
| 05/2018 | 2803169201015 | 316920101 | RIXIMYO C/S.SOL.IN 100MG/10ML VIAL (10MG/ML) 2 VIALS x 10ML | 381.24 | 386.96 | 451.20 |
| 05/2018 | 2803169202012 | 316920201 | RIXIMYO C/S.SOL.IN 500MG/50ML VIAL (10MG/ML) 1 VIAL x 50ML | 946.68 | 960.88 | 1074.55 |
For treatment of CD20-positive non-Hodgkins lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis.
The Fab regions of rituximab binds to the CD20 antigen on B lymphocytes, while the Fc domain recruits antibodies and complements to mediate cell lysis.
0.8 hours (mammalian reticulocytes, in vitro)
* 3.1 L
* 0.34 L/day [RA patients]